恩替卡韦对阿德福韦酯应答不佳患者的疗效分析

恩替卡韦对阿德福韦酯应答不佳患者的疗效分析
陈继林;郭中华;朱珍才;李殊
【期刊名称】《安徽卫生职业技术学院学报》
【年(卷),期】2016(15)3
【摘要】目的：研究3种不同治疗方案对阿德福韦酯(ADV)应答不佳患者的临床疗效和安全性。

方法：A组应用LAM联合ADV挽救治疗，B组应用ETV治疗，C组应用ETV联合ADV治疗。

观察治疗前后患者血清肝功能指标(ALT和AST)、HBeAg和HBVDNA水平的变化。

结果：治疗36、48周后B组和C组肝功能指标改善情况和HBVDNA转阴率明显优于A组（P＜0.05）；与B组相比，C组肝功能指标，HBeAg阳性患者阴转率和HBVDNA转阴率均无明显差异。

结论：ETV治疗ADV应答不佳的慢性乙型肝炎患者疗效确切。

%Aim To investigate the efficacy and safety of three different treatment options in patients with suboptimal response to ADV.Methods:A group patients received the combined therapy with LAM and ADV. B group patients received the therapy with ETV. C group patients received the combined therapy with ETV and ADV. The changes in levels of alanine aminotransferase( ALT), aspartate aminotransferase ( AST), HBeAg and HBV DNA before and after treatment, were measured in three groups.Results:The liver function index and serum HBV DNA clearance rates in B and C group were significantly better than those in A group after 36 and 48 weeks of
treatment(P<0.05).There was no significant difference in the liver function index,HBeAg seroconversion rate and HBV DNA clearance rates between B
group and C group.Conclusion:ETV has good therapeutic effect in treating CHB patients with suboptimal response to ADV.
【总页数】3页(P63-64,66)
【作者】陈继林;郭中华;朱珍才;李殊
【作者单位】莲花县人民医院江西 337100;莲花县人民医院江西 337100;莲花县人民医院江西 337100;莲花县人民医院江西 337100
【正文语种】中文
【中图分类】R541.61
【相关文献】
1.长效干扰素联合恩替卡韦治疗阿德福韦酯应答不佳慢性乙型肝炎患者的疗效观察[J], 刘红霞;雷玎
2.拉米夫定联合阿德福韦酯与换用恩替卡韦单药治疗拉米夫定应答不佳患者的疗效对比 [J], 陈建新
3.拉米夫定、阿德福韦酯与恩替卡韦治疗阿德福韦酯应答不佳慢性乙型肝炎疗效研究 [J], 刘贵章;赵登蕴;冯霞;谢德丰;许静
4.阿德福韦酯应答不佳的慢性乙型肝炎患者加用恩替卡韦进行优化治疗的临床研究[J], 王燕
5.恩替卡韦治疗阿德福韦酯应答不佳HBeAg阳性慢性乙肝患者疗效观察 [J], 刘贵章;李声方;赵登蕴;冯霞;刘贵红
因版权原因，仅展示原文概要，查看原文内容请购买。